Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 374

1.

Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines.

Nicolosi P, Ledet E, Yang S, Michalski S, Freschi B, O'Leary E, Esplin ED, Nussbaum RL, Sartor O.

JAMA Oncol. 2019 Feb 7. doi: 10.1001/jamaoncol.2018.6760. [Epub ahead of print]

PMID:
30730552
2.

Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.

Sonpavde G, Agarwal N, Pond GR, Nagy RJ, Nussenzveig RH, Hahn AW, Sartor O, Gourdin TS, Nandagopal L, Ledet EM, Naik G, Armstrong AJ, Wang J, Bilen MA, Gupta S, Grivas P, Pal SK, Lanman RB, Talasaz A, Lilly MB.

Cancer. 2019 Jan 8. doi: 10.1002/cncr.31959. [Epub ahead of print]

PMID:
30620391
3.

Androgen deprivation therapy in prostate cancer: new findings and questions for the future.

Sartor O.

Lancet Oncol. 2019 Feb;20(2):176-177. doi: 10.1016/S1470-2045(18)30893-3. Epub 2018 Dec 19. No abstract available.

PMID:
30579762
4.

Recycling Discarded Drugs: Improving Access to Oral Antineoplastic Drugs.

Layton JL, Lewis B, Ryan C, Beer TM, Sartor O.

Oncologist. 2018 Dec 19. pii: theoncologist.2018-0565. doi: 10.1634/theoncologist.2018-0565. [Epub ahead of print] No abstract available.

PMID:
30568023
5.

Biomarkers for Programmed Death-1 Inhibition in Prostate Cancer.

Manogue C, Cotogno P, Ledet E, Lewis B, Wyatt AW, Sartor O.

Oncologist. 2018 Dec 12. pii: theoncologist.2018-0546. doi: 10.1634/theoncologist.2018-0546. [Epub ahead of print]

PMID:
30541755
6.

Synergistic Interactions: Targeted Radiopharmaceuticals and Homologous Recombination Repair Alterations in Prostate Cancer.

Sartor O.

Eur Urol. 2018 Dec 1. pii: S0302-2838(18)30940-0. doi: 10.1016/j.eururo.2018.11.041. [Epub ahead of print] No abstract available.

PMID:
30514567
7.

Advanced prostate cancer update 2018.

Sartor O.

Asia Pac J Clin Oncol. 2018 Nov;14 Suppl 5:9-12. doi: 10.1111/ajco.13057. Review.

PMID:
30489036
8.

Conflicts of Interest, Baselga, and Clinical Trialists.

Sartor O.

Oncologist. 2018 Dec;23(12):1394. doi: 10.1634/theoncologist.2018-0663. Epub 2018 Oct 24. No abstract available.

PMID:
30355773
9.

Practical Methods for Integrating Genetic Testing Into Clinical Practice for Advanced Prostate Cancer.

Cheng H, Powers J, Schaffer K, Sartor O.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):372-381. doi: 10.1200/EDBK_205441. Review.

PMID:
30231311
10.

Radium and other alpha emitters in prostate cancer.

Sartor O, Sharma D.

Transl Androl Urol. 2018 Jun;7(3):436-444. doi: 10.21037/tau.2018.02.07. Review.

11.

Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker.

Heinrich D, Bruland Ø, Guise TA, Suzuki H, Sartor O.

Future Oncol. 2018 Oct;14(24):2543-2556. doi: 10.2217/fon-2018-0087. Epub 2018 Jun 21.

12.

Association Between Androgen Deprivation Therapy and Patient-reported Depression in Men With Recurrent Prostate Cancer.

Thomas HR, Chen MH, D'Amico AV, Bennett CL, Kattan MW, Sartor O, Stein K, Nguyen PL.

Clin Genitourin Cancer. 2018 Aug;16(4):313-317. doi: 10.1016/j.clgc.2018.05.007. Epub 2018 Jun 1.

PMID:
29866496
13.

Editorial Comment.

Qureshi ZP, Sartor O, Ablin RJ, Bennett CL.

Urology. 2018 Aug;118:125-126. doi: 10.1016/j.urology.2018.02.050. Epub 2018 May 28. No abstract available.

PMID:
29853290
14.

Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group.

Miyahira AK, Pienta KJ, Morris MJ, Bander NH, Baum RP, Fendler WP, Goeckeler W, Gorin MA, Hennekes H, Pomper MG, Sartor O, Tagawa ST, Williams S, Soule HR.

Prostate. 2018 Aug;78(11):775-789. doi: 10.1002/pros.23642. Epub 2018 May 1. Review.

PMID:
29717499
15.

Laboratory-Based Biomarkers and Liver Metastases in Metastatic Castration-Resistant Prostate Cancer.

Cotogno PM, Ranasinghe LK, Ledet EM, Lewis BE, Sartor O.

Oncologist. 2018 Jul;23(7):791-797. doi: 10.1634/theoncologist.2017-0564. Epub 2018 Apr 26.

PMID:
29700205
16.

Metastatic Prostate Cancer.

Sartor O, de Bono JS.

N Engl J Med. 2018 Apr 26;378(17):1653-1654. doi: 10.1056/NEJMc1803343. No abstract available.

PMID:
29694820
17.

Curing More Prostate Cancer: Thinking Through the Options.

Sartor O.

J Clin Oncol. 2018 May 20;36(15):1466-1468. doi: 10.1200/JCO.2018.78.4835. Epub 2018 Apr 6. No abstract available.

PMID:
29624464
18.

Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).

Mehra N, Dolling D, Sumanasuriya S, Christova R, Pope L, Carreira S, Seed G, Yuan W, Goodall J, Hall E, Flohr P, Boysen G, Bianchini D, Sartor O, Eisenberger MA, Fizazi K, Oudard S, Chadjaa M, Macé S, de Bono JS.

Eur Urol. 2018 Sep;74(3):283-291. doi: 10.1016/j.eururo.2018.02.013. Epub 2018 Feb 28.

19.

First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy.

Valicenti RK, Pugh SL, Trabulsi EJ, Sartor O, Ko EC, Girvigian MR, Rosenthal SA, Shaves ME, Hoffman-Censits JH, Schallenkamp J, Sandler HM.

Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):695-701. doi: 10.1016/j.ijrobp.2017.11.024. Epub 2017 Nov 21.

PMID:
29413282
20.

Metastatic Prostate Cancer.

Sartor O, de Bono JS.

N Engl J Med. 2018 Feb 15;378(7):645-657. doi: 10.1056/NEJMra1701695. Epub 2018 Feb 7. Review. No abstract available.

PMID:
29412780

Supplemental Content

Loading ...
Support Center